DermTech (DMTK) Stock Forecast, Price Target & Predictions
DMTK Stock Forecast
DermTech stock forecast is as follows: an average price target of $15.00 (represents a 21639.13% upside from DMTK’s last price of $0.07) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
DMTK Price Target
The average price target for DermTech (DMTK) is $15.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 21639.13% upside from DMTK's last price of $0.07.
DMTK Analyst Ratings
According to 5 Wall Street analysts, DermTech's rating consensus is 'Buy'. The analyst rating breakdown for DMTK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
DermTech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2022 | - | BTIG | $15.00 | $6.78 | 121.24% | 21639.13% |
The latest DermTech stock forecast, released on Aug 15, 2022 by BTIG company, set a price target of $15.00, which represents a 121.24% increase from the stock price at the time of the forecast ($6.78), and a 21639.13% increase from DMTK last price ($0.07).
DermTech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.07 | $0.07 | $0.07 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of DermTech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DermTech's last price of $0.07. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 19, 2024 | Lake Street | Underperform | Underperform | Hold |
| Apr 19, 2024 | Stephens | Buy | Buy | Hold |
| Apr 19, 2024 | Lake Street | - | Hold | Downgrade |
| Nov 04, 2022 | William Blair | - | Market Perform | Downgrade |
| Aug 17, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 15, 2022 | BTIG | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
DermTech's last stock rating was published by Lake Street on Apr 19, 2024. The company gave DMTK a "Underperform" rating, the same as its previous rate.
DermTech Financial Forecast
DermTech Revenue Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.48M | $2.99M | - | - | $3.72M | $3.17M | - | - | $2.52M | $2.12M | - | - | $1.56M | $1.59M |
| Avg Forecast | $7.30M | $6.70M | $5.80M | $5.60M | $4.45M | $4.48M | $4.28M | $4.23M | $4.20M | $4.19M | $3.95M | $3.94M | $4.04M | $3.90M | $3.70M | $3.43M | $2.55M | $4.66M | $4.82M | $3.75M | $3.33M | $3.42M | $2.85M | $2.11M | $1.82M | $1.14M | $500.00K | $1.00M | $1.08M |
| High Forecast | $7.30M | $6.70M | $5.80M | $5.60M | $4.45M | $4.48M | $4.28M | $4.23M | $4.20M | $4.19M | $3.95M | $3.94M | $4.19M | $3.90M | $3.70M | $3.43M | $2.55M | $4.66M | $4.82M | $3.75M | $3.33M | $3.42M | $2.85M | $2.11M | $1.82M | $1.14M | $500.00K | $1.00M | $1.08M |
| Low Forecast | $7.30M | $6.70M | $5.80M | $5.60M | $4.45M | $4.48M | $4.28M | $4.23M | $4.20M | $4.19M | $3.95M | $3.94M | $3.89M | $3.90M | $3.70M | $3.43M | $2.55M | $4.66M | $4.82M | $3.75M | $3.33M | $3.42M | $2.85M | $2.11M | $1.82M | $1.14M | $500.00K | $1.00M | $1.08M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.17% | - | - | 0.99% | 0.95% | - | - | 1.20% | 1.16% | - | - | 1.56% | 1.47% |
DermTech's average Quarter revenue forecast for Jul 23 based on 2 analysts is $3.70M, with a low forecast of $3.70M, and a high forecast of $3.70M. DMTK's average Quarter revenue forecast represents a 6.36% increase compared to the company's last Quarter revenue of $3.48M (Mar 23).
DermTech EBITDA Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.04M | $-28.89M | - | - | $-29.40M | $-25.89M | - | - | $-11.53M | $-9.28M | - | - | $-6.94M | $-5.08M |
| Avg Forecast | $-7.30M | $-6.70M | $-5.80M | $-5.60M | $-4.45M | $-4.48M | $-4.28M | $-4.23M | $-4.20M | $-4.19M | $-3.95M | $-3.94M | $-4.04M | $-3.90M | $-3.70M | $-3.43M | $-2.55M | $-22.87M | $-4.82M | $-24.53M | $-3.33M | $-3.42M | $-2.85M | $-10.27M | $-1.82M | $-1.14M | $-500.00K | $-5.88M | $-1.08M |
| High Forecast | $-7.30M | $-6.70M | $-5.80M | $-5.60M | $-4.45M | $-4.48M | $-4.28M | $-4.23M | $-4.20M | $-4.19M | $-3.95M | $-3.94M | $-3.89M | $-3.90M | $-3.70M | $-3.43M | $-2.55M | $-18.29M | $-4.82M | $-19.62M | $-3.33M | $-3.42M | $-2.85M | $-8.22M | $-1.82M | $-1.14M | $-500.00K | $-4.71M | $-1.08M |
| Low Forecast | $-7.30M | $-6.70M | $-5.80M | $-5.60M | $-4.45M | $-4.48M | $-4.28M | $-4.23M | $-4.20M | $-4.19M | $-3.95M | $-3.94M | $-4.19M | $-3.90M | $-3.70M | $-3.43M | $-2.55M | $-27.44M | $-4.82M | $-29.44M | $-3.33M | $-3.42M | $-2.85M | $-12.32M | $-1.82M | $-1.14M | $-500.00K | $-7.06M | $-1.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.33% | 11.32% | - | - | 1.20% | 7.76% | - | - | 1.12% | 5.09% | - | - | 1.18% | 4.71% |
undefined analysts predict DMTK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than DermTech's previous annual EBITDA (undefined) of $NaN.
DermTech Net Income Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-30.50M | $-26.91M | - | - | $-29.94M | $-25.44M | - | - | $-15.07M | $-9.40M | - | - | $-7.00M | $-5.12M |
| Avg Forecast | $-9.02M | $-9.37M | $-9.37M | $-9.37M | $-17.70M | $-18.05M | $-18.05M | $-18.39M | $-17.70M | $-18.05M | $-18.05M | $-19.92M | $-19.61M | $-26.51M | $-33.76M | $-31.70M | $-33.42M | $-24.27M | $-35.19M | $-25.26M | $-25.74M | $-22.10M | $-18.51M | $-10.40M | $-18.45M | $-19.09M | $-12.84M | $-5.94M | $-13.88M |
| High Forecast | $-9.02M | $-9.37M | $-9.37M | $-9.37M | $-17.70M | $-18.05M | $-18.05M | $-18.39M | $-17.70M | $-18.05M | $-18.05M | $-19.92M | $-19.61M | $-26.51M | $-33.76M | $-31.70M | $-33.42M | $-19.41M | $-35.19M | $-20.21M | $-25.74M | $-22.10M | $-18.51M | $-8.32M | $-18.45M | $-19.09M | $-12.84M | $-4.75M | $-13.88M |
| Low Forecast | $-9.02M | $-9.37M | $-9.37M | $-9.37M | $-17.70M | $-18.05M | $-18.05M | $-18.39M | $-17.70M | $-18.05M | $-18.05M | $-19.92M | $-19.61M | $-26.51M | $-33.76M | $-31.70M | $-33.42M | $-29.12M | $-35.19M | $-30.32M | $-25.74M | $-22.10M | $-18.51M | $-12.48M | $-18.45M | $-19.09M | $-12.84M | $-7.12M | $-13.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.81% | - | - | 1.19% | 0.99% | - | - | 1.45% | 0.51% | - | - | 1.18% | 0.37% |
DermTech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DMTK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
DermTech SG&A Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.29M | $23.43M | - | - | $24.02M | $20.49M | - | - | $11.68M | $7.95M | - | - | $6.46M | $4.85M |
| Avg Forecast | $39.70M | $36.44M | $31.54M | $30.46M | $24.18M | $24.37M | $23.26M | $23.03M | $22.85M | $22.76M | $21.46M | $21.40M | $21.97M | $21.23M | $20.11M | $18.67M | $13.89M | $25.35M | $26.20M | $20.39M | $18.14M | $18.62M | $15.48M | $11.46M | $9.91M | $6.21M | $2.72M | $5.44M | $5.87M |
| High Forecast | $39.70M | $36.44M | $31.54M | $30.46M | $24.18M | $24.37M | $23.26M | $23.03M | $22.85M | $22.76M | $21.46M | $21.40M | $22.78M | $21.23M | $20.11M | $18.67M | $13.89M | $25.35M | $26.20M | $20.39M | $18.14M | $18.62M | $15.48M | $11.46M | $9.91M | $6.21M | $2.72M | $5.44M | $5.87M |
| Low Forecast | $39.70M | $36.44M | $31.54M | $30.46M | $24.18M | $24.37M | $23.26M | $23.03M | $22.85M | $22.76M | $21.46M | $21.40M | $21.16M | $21.23M | $20.11M | $18.67M | $13.89M | $25.35M | $26.20M | $20.39M | $18.14M | $18.62M | $15.48M | $11.46M | $9.91M | $6.21M | $2.72M | $5.44M | $5.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.69% | - | - | 1.18% | 1.13% | - | - | 1.02% | 0.80% | - | - | 1.19% | 0.83% |
DermTech's average Quarter SG&A projection for Jul 23 is $20.11M, based on 2 Wall Street analysts, with a range of $20.11M to $20.11M. The forecast indicates a -26.30% fall compared to DMTK last annual SG&A of $27.29M (Mar 23).
DermTech EPS Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.00 | $-0.89 | - | - | $-1.00 | $-0.86 | - | - | $-0.68 | $-0.35 | - | - | $-0.53 | $-0.39 |
| Avg Forecast | $-0.26 | $-0.27 | $-0.27 | $-0.27 | $-0.51 | $-0.52 | $-0.52 | $-0.53 | $-0.51 | $-0.52 | $-0.52 | $-0.57 | $-0.57 | $-0.76 | $-0.97 | $-0.91 | $-0.96 | $-0.99 | $-1.01 | $-0.89 | $-0.74 | $-0.64 | $-0.53 | $-0.43 | $-0.53 | $-0.55 | $-0.37 | $-0.46 | $-0.40 |
| High Forecast | $-0.26 | $-0.27 | $-0.27 | $-0.27 | $-0.51 | $-0.52 | $-0.52 | $-0.53 | $-0.51 | $-0.52 | $-0.52 | $-0.57 | $-0.57 | $-0.76 | $-0.97 | $-0.91 | $-0.96 | $-0.99 | $-1.01 | $-0.89 | $-0.74 | $-0.64 | $-0.53 | $-0.43 | $-0.53 | $-0.55 | $-0.37 | $-0.46 | $-0.40 |
| Low Forecast | $-0.26 | $-0.27 | $-0.27 | $-0.27 | $-0.51 | $-0.52 | $-0.52 | $-0.53 | $-0.51 | $-0.52 | $-0.52 | $-0.57 | $-0.57 | $-0.76 | $-0.97 | $-0.91 | $-0.96 | $-0.99 | $-1.01 | $-0.89 | $-0.74 | $-0.64 | $-0.53 | $-0.43 | $-0.53 | $-0.55 | $-0.37 | $-0.46 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.92% | - | - | 1.12% | 1.16% | - | - | 1.60% | 0.66% | - | - | 1.15% | 0.97% |
According to undefined Wall Street analysts, DermTech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DMTK previous annual EPS of $NaN (undefined).
DermTech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DMTK | DermTech | $0.09 | $15.00 | 16566.67% | Buy |
| OM | Outset Medical | $0.53 | $11.00 | 1975.47% | Buy |
| FLGT | Fulgent Genetics | $22.75 | $45.00 | 97.80% | Buy |
| CURI | CuriosityStream | $1.88 | $2.50 | 32.98% | Buy |
| CLPT | ClearPoint Neuro | $11.92 | $12.00 | 0.67% | Buy |
| TMDX | TransMedics Group | $156.08 | $156.86 | 0.50% | Buy |
DMTK Forecast FAQ
Is DermTech a good buy?
Yes, according to 5 Wall Street analysts, DermTech (DMTK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of DMTK's total ratings.
What is DMTK's price target?
DermTech (DMTK) average price target is $15 with a range of $15 to $15, implying a 21639.13% from its last price of $0.069. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DermTech stock go up soon?
According to Wall Street analysts' prediction for DMTK stock, the company can go up by 21639.13% (from the last price of $0.069 to the average price target of $15), up by 21639.13% based on the highest stock price target, and up by 21639.13% based on the lowest stock price target.
Can DermTech stock reach $0?
DMTK's average twelve months analyst stock price target of $15 supports the claim that DermTech can reach $0 in the near future.
What are DermTech's analysts' financial forecasts?
DermTech's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $17.44M (high $17.44M, low $17.44M), average EBITDA is $-17.437M (high $-17.437M, low $-17.437M), average net income is $-72.19M (high $-72.19M, low $-72.19M), average SG&A $94.83M (high $94.83M, low $94.83M), and average EPS is $-2.08 (high $-2.08, low $-2.08). DMTK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $25.4M (high $25.4M, low $25.4M), average EBITDA is $-25.4M (high $-25.4M, low $-25.4M), average net income is $-37.136M (high $-37.136M, low $-37.136M), average SG&A $138.14M (high $138.14M, low $138.14M), and average EPS is $-1.07 (high $-1.07, low $-1.07).
Did the DMTK's actual financial results beat the analysts' financial forecasts?
Based on DermTech's last annual report (Dec 2022), the company's revenue was $14.52M, which missed the average analysts forecast of $15.78M by -8.00%. Apple's EBITDA was $-118M, beating the average prediction of $-54.766M by 116.02%. The company's net income was $-114M, missing the average estimation of $-118M by -3.74%. Apple's SG&A was $94.76M, beating the average forecast of $85.83M by 10.41%. Lastly, the company's EPS was $-3.79, missing the average prediction of $-3.857 by -1.74%. In terms of the last quarterly report (Mar 2023), DermTech's revenue was $3.48M, beating the average analysts' forecast of $3.43M by 1.26%. The company's EBITDA was $-32.038M, beating the average prediction of $-3.434M by 833.08%. DermTech's net income was $-30.495M, missing the average estimation of $-31.698M by -3.80%. The company's SG&A was $27.29M, beating the average forecast of $18.67M by 46.15%. Lastly, the company's EPS was $-1, beating the average prediction of $-0.913 by 9.49%